Celldex Therapeutics
CLDX • NASDAQ
Celldex Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Anthony S. Marucci, with a market cap of $1.5B.
CEOAnthony S. Marucci
Market Cap$1.5B
Biotechnology
Healthcare
Employees160.0
Websitecelldex.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Celldex Therapeutics
Date
Thursday, May 7, 2026 (in 3 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.99
Revenue Estimate
$652.0K
Earnings History
Past 11 earnings reports for Celldex Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2025 | Q3 2025 | -$1.01Est: -$0.89 | -13.5% | -Est: $1.3M | -100.0% |  10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.85Est: -$0.85 | 0.0% | $730.0KEst: $1.3M | -45.8% | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.81Est: -$0.74 | -9.5% | $695.0KEst: $1.1M | -35.6% | 10-Q |
| Feb 27, 2025 | Q4 2024 | -$0.71Est: -$0.73 | +2.7% | $1.2MEst: $1.3M | -10.3% | 10-K |
| Nov 6, 2024 | Q3 2024 | -$0.64Est: -$0.68 | +5.9% | $3.2MEst: $920.0K | +246.8% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.54Est: -$0.60 | +10.0% | $2.5MEst: $820.4K | +204.5% | 10-Q |
| May 6, 2024 | Q1 2024 | -$0.56Est: -$0.69 | +18.8% | $156.0KEst: $920.0K | -83.0% | 10-Q |
| Feb 26, 2024 | Q4 2023 | -$0.83Est: -$0.74 | -12.2% | $4.1MEst: $840.0K | +391.9% | 10-K |
| Nov 2, 2023 | Q3 2023 | -$0.81Est: -$0.68 | -19.1% | $1.5MEst: $580.0K | +161.6% | — |
| Aug 8, 2023 | Q2 2023 | -$0.65Est: -$0.67 | +3.0% | $268.0KEst: $530.0K | -49.4% | 10-Q |
| May 4, 2023 | Q1 2023 | -$0.62Est: -$0.63 | +1.6% | $967.0KEst: $410.0K | +135.9% | 10-Q |